Brief: Hanall Biopharma's Licensed Partner In China Announces Phase 3 Results For Batoclimab In Myasthenia Gravis
06/03/2023 12:46
March 6 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA'S LICENSED PARTNER IN CHINA ANNOUNCES
POSITIVE
TOPLINE PHASE 3 RESULTS FOR BATOCLIMAB IN MYASTHENIA GRAVIS
* HANALL BIOPHARMA CO LTD - TRIAL MET ITS PRIMARY ENDPOINT
AND KEY
SECONDARY ENDPOINTS, WITH A FAVORABLE SAFETY PROFILE
* HANALL BIOPHARMA CO LTD - NO NEW SAFETY SIGNALS IDENTIFIED
Source text for Eikon: ID:nPn1pDl9da
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies